Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

56
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
56
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

558
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
558
Cancer Survival Analysis01:21

Cancer Survival Analysis

321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

38
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
38
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes and Safety Profile of Vancomycin in Outpatient Parenteral Antimicrobial Therapy Services: A Systematic Review.

Antibiotics (Basel, Switzerland)·2026
Same author

Lithium Dispensing Patterns in Dutch Youth: Prevalence, Incidence Dosages, and Duration of Use From 2011 to 2022.

Bipolar disorders·2026
Same author

Sedative Antipsychotic Use by Children and Adolescents in The Netherlands: Dosages, Duration, and Prescribers.

Journal of child and adolescent psychopharmacology·2026
Same author

Imipramine: Do Metabolite Plasma Levels Affect Treatment Response?

Journal of clinical psychopharmacology·2026
Same author

The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress.

Pharmacogenomics·2026
Same author

Semi-Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation.

CPT: pharmacometrics & systems pharmacology·2026

Related Experiment Video

Updated: May 28, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K

From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.

Bram C Agema1,2, Birgit C P Koch3,4, Ron H J Mathijssen5

  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. b.agema@erasmusmc.nl.

Drugs
|February 12, 2025
PubMed
Summary

Model-informed precision dosing tailors cancer drug treatments to individual patients. While not yet standard, studies show it improves outcomes and reduces toxicity for certain oncology drugs, highlighting its future clinical value.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Related Experiment Videos

Last Updated: May 28, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.2K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.2K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

2.7K

Area of Science:

  • Oncology
  • Pharmacokinetics
  • Clinical Pharmacology

Background:

  • Individual variability in drug response necessitates personalized dosing strategies in oncology.
  • Current dosing regimens for oncolytic drugs often lead to side effects and treatment failures.
  • Model-informed precision dosing (MIPD) offers a promising approach to optimize cancer therapy.

Purpose of the Study:

  • To provide a clinical perspective on model-informed precision dosing in oncology.
  • To review prospective implementation and validation studies of MIPD in cancer treatment.
  • To assess the current status and future potential of MIPD in clinical oncology.

Main Methods:

  • Literature review of prospective studies on model-informed precision dosing in oncology.
  • Identification of drugs with implemented or validated MIPD protocols.
  • Analysis of study outcomes focusing on drug exposure, variability, clinical efficacy, and toxicity.

Main Results:

  • Sixteen drugs were identified with prospective MIPD validation/implementation studies.
  • Improved clinical outcomes were observed for busulfan and high-dose methotrexate with MIPD.
  • Reduced toxicities were noted for busulfan and cyclophosphamide treatments.
  • Carboplatin dosing via the Calvert formula, a form of MIPD, did not require further outcome validation due to its established therapeutic window.

Conclusions:

  • Model-informed precision dosing demonstrates added value in oncology.
  • MIPD has the potential to significantly alter future cancer drug dosing regimens.
  • Further integration of MIPD into routine clinical practice is anticipated.